Next Article in Journal
Serial Changes of Serum Growth Factor Levels and Liver Regeneration after Partial Hepatectomy in Healthy Humans
Next Article in Special Issue
Oxidative Stress in Diabetes: Implications for Vascular and Other Complications
Previous Article in Journal
Lentivirus-Mediated ERK2 siRNA Reduces Joint Capsule Fibrosis in a Rat Model of Post-Traumatic Joint Contracture
Previous Article in Special Issue
The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease

Int. J. Mol. Sci. 2013, 14(10), 20845-20876; doi:10.3390/ijms141020845

Protein Glutathionylation in Cardiovascular Diseases
Anna Pastore 1 and Fiorella Piemonte 2,*
Laboratory of Biochemistry, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy; E-Mail:
Unit of Neuromuscular and Neurodegenerative Diseases, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Author to whom correspondence should be addressed; E-Mail:; Tel.: +39-6-6859-2102; Fax: +39-6-6859-2024.
Received: 29 August 2013; in revised form: 2 October 2013 / Accepted: 8 October 2013 /
Published: 17 October 2013


: The perturbation of thiol-disulfide homeostasis is an important consequence of many diseases, with redox signals implicated in several physio-pathological processes. A prevalent form of cysteine modification is the reversible formation of protein mixed disulfides with glutathione (S-glutathionylation). The abundance of glutathione in cells and the ready conversion of sulfenic acids to S-glutathione mixed disulfides supports the reversible protein S-glutathionylation as a common feature of redox signal transduction, able to regulate the activities of several redox sensitive proteins. In particular, protein S-glutathionylation is emerging as a critical signaling mechanism in cardiovascular diseases, because it regulates numerous physiological processes involved in cardiovascular homeostasis, including myocyte contraction, oxidative phosphorylation, protein synthesis, vasodilation, glycolytic metabolism and response to insulin. Thus, perturbations in protein glutathionylation status may contribute to the etiology of many cardiovascular diseases, such as myocardial infarction, cardiac hypertrophy and atherosclerosis. Various reports show the importance of oxidative cysteine modifications in modulating cardiovascular function. In this review, we illustrate tools and strategies to monitor protein S-glutathionylation and describe the proteins so far identified as glutathionylated in myocardial contraction, hypertrophy and inflammation.
glutathione; S-glutathionylation; myocardial; contraction; metabolism; hypertrophy; inflammation; cardiovascular diseases; atherosclerosis

1. Introduction

Oxidative stress represents an imbalance between ROS production and the cellular antioxidant defense system. In stress conditions, ROS levels increase and, because of their high reactivity, participate in a variety of chemical reactions. They are involved in cell damage, necrosis and apoptosis via oxidation of lipids, proteins and DNA and also provoke endothelial dysfunction, infiltration and activation of inflammatory cells [1]. ROS generation can be finely controlled and can constitute a physiologic signaling pathway, also mediating S-glutathionylation.

Protein glutathionylation is becoming increasingly recognized as playing a causative role in cardiovascular disorders (CVDs). Indeed, it regulates numerous physiological processes involved in cardiovascular homeostasis and/or perturbed in disease, including myocyte contraction, oxidative phosphorylation, protein synthesis, vasodilation, glycolytic metabolism and response to insulin. Therefore, perturbations in protein glutathionylation status may contribute to the etiology of cardiovascular diseases, such as myocardial infarction, cardiac hypertrophy and atherosclerosis. In this review, we discuss the glutathione-related modifications underlying redox signaling in CVDs focusing on myocardial contraction, metabolism, proliferation, hypertrophy and inflammation.

2. Protein-S-Glutathionylation Status in Cardiovascular Diseases

Protein S-glutathionylation is emerging as a critical signaling mechanism in cardiovascular diseases, because it regulates numerous physiological processes involved in cardiovascular homeostasis, including myocyte contraction, oxidative phosphorylation, protein synthesis, vasodilation, glycolytic metabolism and response to insulin [25]. Thus, perturbations in protein glutathionylation status may contribute to the etiology of cardiovascular diseases, such as myocardial infarction, cardiac hypertrophy and atherosclerosis.

2.1. Myocardial Infarction

Overall protein glutathionylation increases following ischemia-reperfusion (IR), with the majority of the glutathionylation events occurring early in the reperfusion period [6]. Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was identified as a prominent cardiac protein glutathionylated during IR with loss of enzyme function, suggesting that GAPDH glutathionylation is likely inhibitory in vivo. The effect of this inhibition may be: (a) a block of glycolysis characteristic of ischemic injury; (b) an interference with nuclear translocation, resulting in increased apoptosis or (c) a homeostatic answer to the excess of oxidants. Of note, GAPDH activity is restored at the end of the reperfusion, thus suggesting that glutathionylation may constitute a temporary protection of catalytic cysteines from irreversible oxidation. Chen and Ogut [7] further evidenced the glutathionylation of actin in a rat model of in vivo IR. Studies on isolated G-actin indicated that glutathionylation delayed its rate of polymerization and decreased the cooperativity of its binding to tropomyosin [8], suggesting that actin glutathionylation may contribute to the decline in cardiac contractility observed during ischemia. In contrast, mitochondrial complex II seems to be deglutathionylated during IR [9], indicating that a single oxidative stimulus can affect glutathionylation in different directions and highlighting also the potential critical role of Grx in myocardial infarction. Mouse models of embryonic Grx1 knockout, as well as overexpression of Grx1 and Grx2 transgenes, were developed and subjected to in vivo and ex vivo IR [1012]. Such experiments suggest a cardioprotective role for Grx isoforms, but additional studies are however needed. An attractive candidate in cardio-protection is mitochondrial complex I, in which glutathionylation of the 51- and 75-kD subunits is correlated with electron transport inhibition and increased production of superoxide [13]. Glutathionylation of complex I, with associated increases in superoxide production, would be expected to increase cytochrome c release and caspase activation, inducing survival signals and contributing to infarct size and cardiac dysfunction. The deglutathionylation of complex I by Grx2 could represent an upstream event responsible for modulating these effects in Grx2 transgenic animals.

2.2. Cardiac Hypertrophy

Multiple signaling pathways contribute to the development of pathological cardiac hypertrophy [14]. Among them, the Raf/MEK/ERK pathway can be stimulated either by G protein-coupled receptor ligands (e.g., angiotensin II, endothelin) or by mechanical stretch resulting in induction of protein synthesis. Pimentel et al. [15] showed that mechanical strain stimulating the Raf/MEK/ERK pathway was dependent upon glutathionylation of Ras in neonatal rat ventricular myocytes, a small GTPase implicated in myocyte growth signaling. The authors demonstrated that glutathionylated Ras was formed in response to a physiological stimulus (mechanical strain) and that glutathionylation induced the increase of Raf and GTP binding regulating the protein synthesis, important in cardiac hypertrophy. Thus, investigating the Ras glutathionylation status in animal models of cardiac hypertrophy may provide insight into the progression of the disease in vivo.

2.3. Atherosclerosis

The precise role of glutathionylation in the development and progression of atherosclerosis is unknown; however, conditions within atherosclerotic plaques (e.g., hypoxia, oxidative stress, oxidized LDL, and inflammation) have been shown to promote glutathionylation in other contexts [6,16,17], and Grx has been reported to associate with areas of oxidative stress within the vasculature [18].

Protein glutathionylation increases in human macrophages exposed to oxidized LDL (oxLDL), a major component of atherosclerotic plaques [17] and, together with glutathione (GSH) depletion, increased glutathionylated proteins seem to be implicated in oxLDL-induced macrophage death in vitro [19]. The role of specific glutathionylated proteins in macrophage cell death is not yet determined, nor is it known whether global protein glutathionylation increases in other cells types exposed to oxLDL. Patients with atherosclerosis of the extremities (i.e., atherosclerosis obliterans (ASO)) exhibit increased glutathionylation of serum proteins, and a positive correlation between disease progression and the level of protein glutathionylation was found [20]. The authors identified ApoB100, the major component of LDL, as a target for increased glutathionylation in ASO, but if the glutathionylated apoB100 represents a disease marker or contributes to the pathogenesis of ASO remains an open question.

Sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) glutathionylation represents a physiological, cGMP-independent mechanism of vessel relaxation, and it is disrupted during atherosclerosis [21]. Site-directed mutagenesis and mass spectroscopic analysis suggested that glutathionylation of Cys674, located in the cytosolic-facing hinge domain, was responsible for SERCA activation. The irreversible oxidation (i.e., sulfonic acid formation) of SERCA’s Cys674 during atherosclerosis prevents its reversible glutathionylation and may contribute to the impaired vasodilation in atherosclerotic smooth muscle. Analysis of cysteine modifications from atherosclerotic vs. normal rabbit aortas showed increased sulfonate formation, corresponding to decreased glutathionylation, reduced NO-induced relaxation and Ca2+ reuptake.

The glutathionylation of Ras may also contribute to vascular hypertrophy implicated in atherosclerosis and hypertension in rat vascular smooth muscle cells (VSMCs) [22]. Indeed, the treatment of VSMCs with angiotensin II, which induces vascular hypertrophy, led to glutathionylation and activation of Ras, resulting in increased phosphorylation of p38 and Akt and increased protein synthesis. These effects were dependent upon NADPH oxidase activation and ROS formation [23,24], and were blocked by overexpression of Grx1 or mutation of Ras at the site of glutathionylation (Cys118). The glutathionylated Ras may contribute to atherosclerosis by mediating the response to oxLDL in endothelial cells. Indeed, the treatment of bovine aortic endothelial cells with peroxynitrite led to Ras glutathionylation and activation of both ERK and Akt pathways, and some of these observations were recapitulated with oxLDL treatment [25].

A complex relationship exists between protein glutathionylation, Grx and Akt activity within the cardiovascular system [26]. Akt is emerging as a signaling molecule within the heart and vasculature, implicated in various pathological signaling events, as well as in normal development and homeostasis [27]. Deglutathionylation by Grx could participate in regulating the balance between physiological and pathophysiological Akt activation.

An emerging contributor to atherogenesis may further be represented by the tumor necrosis factor-alpha (TNFα), which is thought to induce expression of adhesion molecules on endothelial cells and contribute to vascular smooth muscle cell apoptosis [28]. Pan and Berk [29] treated endothelial cells with a combination of TNFα and cycloheximide and observed Grx activation, pro-caspase-3 deglutathionylation, caspase-3 cleavage and increased apoptosis. This study raises an important question about the potential role of Grx in atheroprotection. However, the role of Grx in cardiovascular disease may not be entirely straightforward, with its roles in disease protection or progression dependent upon cell type, extracellular stimuli, etc.

3. Tools and Strategies to Monitor Protein S-Glutathionylation

S-glutathionylation is a redox-dependent post-translational modification with growing relevance in signal transduction. Initially, the meaning of the S-glutathionylation was thought to be the protection of cysteine residues against over oxidation to sulfenic (RSOH), sulfinic (RSO2H) or sulfonic (RSO3H) acids, which can lead to protein inactivation [30]. Later, it was shown that protein glutathionylation directly affects enzyme activities, suggesting a modulator role for this process [2]. At the present time, S-glutathionylation is considered a regulatory event in “redox signaling”, and it is involved in several pathways that often cross-talk with each other. The reversibility of this process is a key element to ascribing regulatory, as well as signaling functions to S-glutathionylation [31]. The de-glutathionylation may occur via direct thiol/disulfide exchange reactions with GSH, once an appropriate GSH/GSSG ratio has been restored, or by the intervention of glutaredoxin. This enzyme not only deglutathionylates specific proteins, but in the presence of a glutathione-radical generating system, it is also capable of catalyzing S-glutathionylation [31].

Glutathionylation and deglutathionylation can also be catalyzed by other enzymes, such as thioredoxin (Trx) and protein disulfide isomerase (PDI). All these enzymes are characterized by the presence of a CXXC motif in the active site where the two cysteines cycle between the reduced form and the oxidized one during the catalytic reaction [32]. Recently, catalysis of de-glutathionylation by sulfiredoxin (Srx), which was previously described as an enzyme that catalyzes the reduction of cysteine-sulfinic acid in peroxiredoxins, was reported [33]. Most recently, a role for the glutathione transferase omega 1 (GSTO1-1) in the glutathionylation cycle was described [34].

Taken together, these two process (glutathionylation and deglutathionylation) are defined as the S-glutathionylation cycle (Figure 1). Relative to the proteome, although new target proteins appear regularly in the literature, the actual number of S-glutathionylated proteins is probably not large and might best be described as the “glutathionome” [35].

Four major types of experimental strategies have been developed to detect protein S-glutathionylation. The first method allows the quantification of the total amount of glutathionylated proteins. This technique can be used in vivo or in vitro and allows quantification of glutathionylated proteins, but is not able to detect glutathione adducts on specific proteins. The second is based on the use of labeled glutathione, by either 35S radiolabeling or biotinylation. These techniques can be used in vivo or in vitro and allow detection of glutathione adducts on S-thiolated proteins. The third type is based on the detection of glutathionylated proteins without labeling of the glutathione pool using anti-glutathione antibodies. Both techniques use a bottom-up proteomic approach to identify S-glutathionylated proteins. The fourth, and most recent, approach is top-down proteomics, which allows S-glutathionylated proteins identification on whole protein extract from cells without the use of labeling or an anti-glutathione antibody [36].

3.1. Quantification of Total S-Glutathionylated Proteins

A number of methods that allow for quantification of total S-glutathionylated proteins either in vitro or in vivo were described. All methods use sample lysis or homogenization in non-reducing buffer containing N-ethylmaleimide to eliminate free thiols, followed by protein precipitation, reduction of the glutathionyl-protein adducts, and derivatization of the protein thiols (PS-SH) or the free GSH, so formed with various fluorescence probes (Figure 2). Finally, fluorescence is measured by fluorometric analysis with or without prior HPLC separation. Using the fluorescence probe, ThioGlo-1™, Townsend and collaborators [37] analyzed the S-glutathionylation of liver proteins before and after treatment with the glutathione disulfide mimetic, NOV-002. Most recently, by using monobromobimane as the fluorescence probe and HPLC separation, we found that protein-bound glutathione is increased in lymphocytes of cobalamin c patients and in patients with X-linked adrenoleukodystrophy [38,39]. This method can also be used to monitor antioxidant therapy, as demonstrated recently in children with mitochondrial encephalomyopathies [40]. Using 2,3-naphthalenedicaboxaldehyde as the fluorescence probe and direct fluorescence measurement, Menon and Board [41] quantitatively assayed the total content of S-glutathionylated proteins in several mouse tissues treated with the anti-cancer drug, doxorubicin, and in a lymphoblastoid cell line before and after a pro-oxidant stimulus. Their method allows a rapid and simple quantification of changes in the level of protein glutathionylation in response to oxidative stress and drug treatment.

These methods can be useful for the in vivo and in vitro quantification of total protein glutathionylation, but other methods will have to be employed for the exact identification of single glutathionylated proteins.

3.2. Methods Based on Labeling of Glutathione

3.2.1. 35S Radiolabeling

Radiolabeled glutathione is a convenient tool for the analysis of protein glutathionylation, which allows a very sensitive and quantitative detection of glutathionylated proteins. In vitro, the glutathionylation of several proteins has been analyzed using 35S-GSH [4245]. Radiolabeling of the glutathione pool by 35S-cysteine has been the most widely used method for proteomic analysis of glutathionylated proteins in vivo (Figure 3). The first step consists of inhibition of protein synthesis with cycloheximide, followed by incubation in the presence of 35S-cysteine. After the labeling step, cells are placed under oxidative stress conditions, by the addition of oxidants, such as H2O2 and diamide, or NO donors, such as nitrosoglutathione (GSNO) or PABA/NO. Alternatively, S-thiolation is obtained by increasing ROS production, for example, by induction of the respiratory burst in monocytes, which leads to S-thiolation of several proteins [4648]. After this second step, proteins can be extracted and separated on non-reducing mono- or bi-dimensional gels. S-thiolated proteins can be visualized after gel drying by autoradiography or phosphor imaging technologies. DTT treatments of radioactive samples should lead to a loss of the radioactive signal, thereby confirming that the labeling is linked to S-thiolation. With the development of proteomic approaches, this method was further adapted for large-scale identification of S-thiolated proteins using 2D gels and peptide mass fingerprinting. The first study was performed on human T lymphocytes, where 38S-thiolated proteins could be identified after treatment with diamide or H2O2[49]. Subsequently, similar studies allowed identification of a number of S-thiolated proteins in several cell types and organisms. The 35S-cysteine labeling method has, however, several major drawbacks. The major problem resides in the necessary pretreatment with protein synthesis inhibitors that could perturb cell physiology. Moreover, this method does not allow for discrimination between the different possible types of S-thiolation, although glutathionylation is considered to be predominant. Indeed, some of the radiolabeled proteins might not be glutathionylated, but cysteinylated or S-thiolated by other low-molecular-weight compounds synthesized from cysteine. The contribution of glutathionylation to the total labeling can be estimated in the presence of buthionine sulfoximine (BSO), a specific inhibitor of the glutathione synthesis. In human T-cells, more than 80% of the radiolabeling is lost in the presence of BSO, thereby confirming that glutathionylation is the major type of S-thiolation [49]. Another limitation is linked to the necessity to perform 2D gels to visualize the S-thiolated proteins. The loading limit of 2D gels allows only the identification of abundant proteins. Though this problem might be partly overcome by fractionation of the extract before 2D electrophoresis, low abundance proteins will probably not be identified with this method. Similarly, proteins with a high or low pI or a very high or very low molecular weight will not be detected. The sensitivity of this method is also limited by the low specific activity of the 35S-labeled glutathione pool. Another drawback is that the use of this method is restricted to cell cultures, thereby avoiding studies on whole organisms under physiological conditions and strongly limiting genetic analyses. Finally, this method can only detect proteins undergoing glutathionylation during the treatment, while some proteins might be already glutathionylated under basal conditions.

Despite its numerous limitations and drawbacks, the 35Scysteine labeling method has allowed identification of most known S-thiolated proteins. The method can be useful for identification of most abundant S-thiolated proteins in cell cultures, while other methods will have to be employed for the analysis of low abundance proteins.

3.2.2. Biotinylated Glutathione

Biotinylated glutathione can be easily synthesized in vitro either in the reduced (BioGSH) or in the oxidized (BioGSSG) forms. The synthesis of these compounds is based on the use of a water-soluble biotinylation reagent (sulfosuccinimidyl-6-(biotinamido)-hexanoate, sulfo-NHS-biotin). This reagent is used to couple biotin to the primary amino groups of glutathione under mild alkaline conditions using an amine-free buffer. After the reaction is completed, any remaining biotinylation reagent is quenched by the addition of an amine-containing buffer to a 10-fold molar excess of the starting sulfo-NHS-biotin concentration. The biotinylation reagent is reacted with the reduced form (GSH) at a 1:1 molar ratio, while a 2:1 molar ratio is used with the oxidized form. However, when the biotinylated reagent is coupled to reduce glutathione, it can react with the sulfur atom of glutathione, decreasing the total amount of free-thiol biotinylated glutathione. In the case of oxidized glutathione, the presence of two primary amino groups at the opposite ends of GSSG leads to the incorporation of two biotin moieties into the GSSG molecule. The resulting biotinylated glutathione molecules can be used as an effective marker for oxidant induced S-glutathionylation. The presence of the biotin moiety on glutathione allows for a sensitive and specific detection of glutathionylated proteins by non-reducing Western blot probed with commercially available streptavidin-horseradish peroxidase or anti-biotin antibodies. When BioGSSG is used, it mimics a defined component of oxidative stress, namely, a shift in the glutathione redox couple to the oxidized disulfide state. By contrast, BioGSH does not induce oxidative stress, and it is used in combination with oxidants, such as diamide or H2O2. Biotin-labeled proteins can be affinity purified on avidin-conjugated agarose beads. After extensive washing with detergent buffer, proteins bound to avidin via a mixed disulfide bond with biotinylated glutathione can be eluted by incubation with reducing agents (DTT or β-mercaptoethanol) and identified by mass spectrometry (Figure 4). BioGSSG allowed identification of 11 glutathionylated proteins by LC-MS/MS in rat heart during post-ischemic reperfusion [50].

Biotin-based strategies for proteomic analysis of glutathionylated proteins have several advantages compared to 35S-cysteine labeling methods. First, protein synthesis does not have to be inhibited during the oxidative stress treatment. Second, this method only detects glutathionylated proteins rather than all S-thiolation targets. Third, the affinity purification is very specific and overcomes 2D gel limitations. The targets can be analyzed on 2D gels only loaded with glutathionylated proteins rather than total extracts, allowing detection of significantly less abundant proteins. Alternatively, eluted proteins can be analyzed by highly sensitive and high throughput proteomic methods, such as nanoLC-MS/MS. Finally, the presence of the biotin tag on the proteins of interest allows their detection by multiple methods, such as immunoblotting with or without prior immunoprecipitation using biotin antibodies or horseradish peroxidase-conjugated avidin (HRP-avidin) [51], batch or column-based affinity purifications or cellular localization by fluorescence microscopy [50]. The major drawback of the methods based on biotinylated glutathione is the presence of the bulky biotin tag on the glutathione molecule that might perturb the function of proteins interacting with glutathione and especially those controlling glutathionylation. A common drawback of both labeling methods is that they do not give access to proteins glutathionylated under basal conditions.

3.3. Methods Utilizing Anti-Glutathione Antibodies

Glutathionylated proteins can also be detected with commercially available anti-glutathione antibodies. Methods based on such antibodies are promising, since they could overcome most problems encountered with 35S and biotin labeling methods. Indeed, with anti-glutathione antibodies, glutathionylated proteins could be analyzed under more physiological conditions, since no pretreatment is required. This could allow detection of glutathionylated proteins by Western blots with 1D or 2D gels, by immunoprecipitation or even by immunocytolocalization. Almost all published studies have been performed with a mouse monoclonal antibody (Virogen, Watertown, MA, USA), which has proven useful to analyze, in vivo, the glutathionylation of actin [5257], myosin [57,58], tubulin [56,59,60], HSP70 [61,62], neurofilaments [56] and Type 1 calcium release channels [63,64]. These proteins can probably be detected in total extracts, because they are very abundant. Indeed, this antibody exhibits a low sensitivity that greatly limits the number of glutathionylated proteins detected. This sensitivity issue can be partly overcome by working on purified proteins or fractions enriched with the protein of interest, even if this preliminary enrichment is only possible when the target protein is known, and it is therefore not applicable for proteomic identification of unknown glutathionylated proteins. In total extracts, the anti-glutathione antibody only detects a few abundant proteins [50]. Every proteomic study based on the use of this antibody led to the identification of only four or five abundant proteins, such as HSP70 or actin [62,65,66]. The number of glutathionylated proteins detected appears higher with strong inducers of glutathionylation, such as PABA/NO [33,67]. A major drawback of the anti-glutathione antibody concerns its specificity. Indeed, glutathione is a very flexible molecule that can potentially exhibit hundreds of conformations, either in solution or bound to proteins [68]. Hence, the affinity of the antibody for glutathionylated proteins is likely to vary greatly, depending on the conformation of the glutathione adduct and the environment of the thiolated cysteine. Overall, the anti-glutathione antibodies currently available can prove useful for the analysis of individual proteins, but do not appear to be appropriate for large-scale detection of glutathionylated proteins by proteomic approaches.

3.4. Top-Down Proteomics Approach

Most recently, a top-down proteomics approach was used to identify protein S-glutathionylation and S-cysteinylation in Salmonella typhimurium in response to infection-like conditions [36]. Liquid chromatography-coupled mass spectrometry (LC-MS)-based top-down proteomics is an emerging method in which whole/intact proteins are separated and fragmented directly into the mass spectrometer to achieve both protein identification and characterization. This is in contrast to the well-established bottom-up LC-MS approach in which proteins are digested with a protease into smaller peptides and analyzed by tandem mass spectrometry to give protein identity from peptide level information. Bottom-up proteomics is still a good method given its ability to identify large numbers of proteins, but is not able to distinguish proteoforms [69], which constitute the functional proteome essential to understand biological systems. With this approach, S-glutathionylated proteins could be identified in biological systems without using any labeling procedures, thus allowing sensitive and specific access to proteins glutathionylated under basal conditions.

3.5. Other Methods

Several other methods have been proposed to detect and identify a numbers of glutathionylated proteins. Some studies have used immobilized glutathione or its analogs to affinity purify proteins containing reactive cysteines susceptible of undergoing glutathionylation. While these methods do not allow in vivo analyses, they may be complementary to techniques based on radiolabeled or biotinylated glutathione for the analysis of glutathionylation targets in vitro. GSH and GSSG affinity matrices allowed for identification of seven candidate glutathionylated proteins by Western blot [70] and were also used to study the glutathionylation of SERCA [21] and p53 [71]. Liquid chromatography/electrospray ionization mass spectrometry (ESI-MS) [72] or cation exchange HPLC coupled with spectrophotometric detection [73] were used for the quantification of erythrocytes glutathionyl-hemoglobin (GS-Hb) content.

Recently, a bioinformatics framework to predict S-glutathionylation sites by employing machine learning methods based on protein sequences was reported [74]. All the S-glutathionylation proteins and their corresponding modification sites are manually collected from the literature, so that a series of classifiers are built to predict S-glutathionylation sites based on support vector machines (SVMs). Different features are extracted from protein sequences for prediction of S-glutathionylation sites. Results obtained in five-fold cross-validation demonstrate the effectiveness of this method, with a Receiver Operating Characteristic curve (AUC) score of 0.879. This method could provide putative S-glutathionylation sites for future experimental verification.

4. Physiological Effects of Protein Glutathionylation

4.1. Myocardial Contraction

4.1.1. Ryanodine Receptor

Calcium release through cardiac ryanodine receptors (RyR2) triggers heart muscle contraction. RyR2 is a large ligand-activated intracellular Ca2+ release channel located at the endoplasmic and sarcoplasmic reticulum (SR). In the myocardium, RyR2 plays a crucial role in mediating excitation contraction coupling by increasing intracellular Ca2+ after an action potential. It is regulated by direct phosphorylation at different sites by cAMP-dependent kinase (PKA) or calmodulin kinase II (CaMKII). In addition to phosphorylation, direct oxidation has also been implicated as a regulator of the channel’s function. This is not surprising, considering that this tetrameric channel contains 364 cysteines with about 84 of them having free thiol groups. Basal S-glutathionylation of RyR2 was discovered in microsomal fractions enriched in SR vesicles isolated from dog cardiac ventricular muscle [75]. Under physiological conditions, such as tachycardia and exercise, RyR2S-glutathionylation increases, and this suggests that cardiac cells utilize this redox modification to increase RyR2 activity when the demand is increased [76]. The RyR2 activity is enhanced also in heart failure, and this presumably contributes toward decreasing calcium content in sarcoplasmic reticulum and inducing calcium release abnormalities observed in heart failure. The number and identity of reactive cysteines in the RyR2 are presently unknown, like the physiological sources of ROS responsible for RyR2 redox modifications. With both exercise and tachycardia, the administration of the NADPH oxidase (NOX) inhibitor, apocynin, prevented RyR2S-glutathionylation and attenuated Ca2+ release from the SR. However, it is important to consider that apocynin may not be a specific NADPH inhibitor, but rather, an antioxidant, which could also explain its ability to decrease RyR2S-glutathionylation in these models [77]. The redox state of RyR2 is altered in heart failure, leading to enhanced RyR2 activity, which presumably contributes to decrease SR calcium content and induce other calcium release abnormalities observed in heart failure. Therefore, greater understanding of RyR2 redox modulation is necessary to counteract the deleterious consequences of RyR2 activity deregulation caused by oxidative stress [78].

4.1.2. Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA)

Of the three mammalian members belonging to the sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) family, SERCA2 is evolutionarily the oldest and shows the most wide tissue-expression pattern [79]. Two major SERCA2 splice variants are well characterized: the muscle-specific isoform, SERCA2a, and the housekeeping isoform, SERCA2b. SERCA2b is found in the ER of most cell types and is considered the housekeeping isoform. The muscle-specific isoform, SERCA2a, is expressed in the sarcoplasmic reticulum (SR) of the heart and slow-twitch skeletal muscle. Several interacting proteins and post-translational modifications of SERCA2 were identified, which may modulate the activity of the Ca2+ pump. SERCA2, the dominant isoform in the heart and vasculature, acts as an inward pump that utilizes the energy from ATP to drive the removal of intracellular free Ca2+ into the SR Ca2+ store [80]. The ability of this pump to maintain cytosolic free Ca2+ and the quantity available in the SR store during systole makes SERCA2 a major determinant of cardiac contractility and smooth muscle tone. The activity of SERCA2 is regulated by the accessory membrane protein, phospholamban (PLN). PLN binds to and inhibits SERCA2 when dephosphorylated. The phosphorylation of PLN by PKA at Ser-16 or calmodulin-dependent protein kinase II (CaMKII) at Thr-17 dissociates PLN from SERCA and relieves its inhibitory effect on SERCA activity. In addition, direct S-glutathionylation can modulate the SERCA2’s activity, and this occurs on the reactive thiol of Cys674[81]. Notably, under physiological conditions in arterial smooth muscle, endothelium-derived NO combines with the superoxide radical to form the highly reactive peroxynitrite (ONOO−). This then reacts with cytosolic glutathione and reversibly glutathionylates a number of free SH groups in SERCA, of which the one in Cys674 is pivotal in activating SERCA2 [21].

In intact cells or arteries, S-glutathionylation of the pump by NO (in the form of its active “effector” peroxynitrite) results in accelerated Ca2+ uptake and in relaxing of vascular smooth muscle. In atherosclerotic aorta, NO does not increase S-glutathionylation of SERCA, because of the irreversible oxidation of Cys674 to sulfonic acid, and as a result, fails to stimulate its activity [21,81]. S-glutathionylation affects Ca2+ homeostasis also in cultured aortic endothelial cells, where diamide promoted Ca2+ release from inositol 1,4,5-trisphosphate (IP3)-sensitive internal Ca2+ stores and elevated basal free cytosolic Ca2+ concentration. This effect was related to the glutathionylation of the IP3 receptor and the plasmalemmal Ca2+ ATPase pump [82].

In a rabbit model of atherosclerosis, SERCA S-glutathionylation in abdominal aorta was increased, and a decreased relaxation was observed; thus, the loss in vessel relaxation in the aorta of rabbits with atherosclerosis could be explained by inhibition of S-glutathionylation [21]. In the heart, stimulation of SERCA activity and cardiomyocyte contractility by the thiolating nitroxyl anion generator, Angeli’s salt, is also accompanied by S-glutathionylation and stimulation of SERCA activity [83].

4.1.3. The Endothelial Nitric Oxide Synthase (eNOS)

The endothelial nitric oxide synthase (eNOS) is constitutively expressed and is involved in regulating normal cellular function by converting l-arginine to l-citrulline. eNOS generates nitric oxide (NO), which has different roles in the cardiovascular system, including the control of blood pressure and smooth muscle tone, regulation of platelet aggregation, development of arteriosclerosis, cytoprotection and cytotoxicity [3]. eNOS can be modulated by direct S-glutathionylation [84]. The S-glutathionylation of eNOS decreases its activity and increases O2− formation, as measured using paramagnetic spin trapping. Cys689 and Cys908 in the reductase domain have been identified as the sites of oxidation by GSSG using liquid chromatography-tandem mass spectrometry, and molecular modeling around the sites of S-glutathionylation revealed a dysfunctional alignment between the FAD and FMN binding domains that decreases the electron transfer between flavins and improves access to oxygen, then converts it to O2−. The mutation of these cysteine residues had little effect on eNOS activity, but attenuated O2− formation after treatment with GSSG, thus demonstrating that the two cysteines are key redox sites in eNOS activity regulation. Under pathological oxidative stress, S-glutathionylation of eNOS can cause a loss in endothelium-dependent relaxation, leading to hypertension [84,85]. This redox mechanism of eNOS modulation was found to occur in hypertensive rats, which had a normal response to an NO-donor, but had a large deficit in acetylcholine-mediated relaxation compared to control animals. Interestingly, in the aorta of these rats, there was increased eNOS S-glutathionylation, and the relaxation abnormalities were rectified by the addition of a thiol-specific reducing agent (DTT) to isolated vessels. These results suggest that under pathological oxidative stress, S-glutathionylation of eNOS can cause a loss in endothelium-dependent relaxation, leading to hypertension.

4.1.4. Na+-K+ ATPase

The cardiac Na+-K+ pump is a heterodimeric membrane protein composed of a 100-kDa α subunit (consisting of 10 transmembrane segments) and a glycosylated 55-kDa type II membrane protein, the β subunit [86,87]. The active transport mediated by this ubiquitous ATP-dependent pump maintains the electrochemical gradients for Na+ and K+ across cell membranes in all tissues and is estimated to consume up to 20%–30% of ATP under resting conditions [88]. However, the electrochemical energy of the Na+ gradient also serves in “secondary” co- and counter-transport of other ions and of important organic compounds with broad implications for cellular physiology and pathophysiology [86]. In heart, the secondary active transport of Ca2+ has received particular attention for its role in excitation-contraction coupling. Raised intracellular Na+ levels play a key role in the Ca2+-dependent contractile abnormalities and arrhythmias characterizing heart failure [89,90]. Indeed, a small increase in Na+ causes an increase in Ca2+ and enhances contractility under physiological conditions. In the presence of larger increases of intracellular Na+ and Ca2+, Ca2+ is spontaneously released from the sarcoplasmic reticulum (SR) during diastole. Therefore, understanding the mechanisms of pump regulation is critical and may be very useful in treatments [91].

The β1 subunit of the Na+-K+ pump is a substrate for glutathionylation that occurs at cysteine 46, causing pump inhibition. This β1 subunit contains seven cysteine residues. Six of these, located in the extracellular domain, are linked by three disulfide bonds [92]. Only one cysteine, Cys-46, has a free sulfhydryl group and is a good candidate for glutathionylation. Mutagenesis of α11 Na+-K+ pump heterodimers, expressed in Xenopus oocytes, confirmed that Cys-46 was reactive and established that glutathionylation of it was causally related to Na+-K+ pump inhibition. The β2 and β3 subunits have only six cysteine residues linked by disulfide bonds; thus, β23 heterodimers are not sensitive to oxidation-induced inhibition [93]. Liu et al. [94] have recently examined whether glutathionylation depends on the conformational changes in the Na+-K+ pump cycle. Indeed, the crystal structure indicates that the side chain of cysteine 46 is exposed to the lipid bulk phase of the membrane and not accessible to the cytosolic glutathione [95,96]. However, the Na+-K+ pump undergoes large changes in molecular structure during its catalytic cycle [97]. The Na+-K+ pump undergoes changes between states, referred to as E1 and E2 conformations, during its pumping cycle, with substantial movement of β subunits relative to α subunits [98]. This conformational change from E2 to E1 may shift the Cys-46 of the β1 subunits into a cytosolic domain, facilitating glutathionylation. Liu et al. [94] have measured β1 subunit glutathionylation in membrane fragments and in ventricular myocytes. Large signals for glutathionylation were detected with the biotin-GSH and GSH antibody techniques when membrane fragments were suspended in a solution that stabilizes the E1ATP conformation of the Na+-K+-ATPase, whereas the signal was much smaller in a solution stabilizing the E2 conformation. No difference in glutathionylation between the E2 and K-bound E2 was observed. The exposure of myocytes to ouabain decreased glutathionylation, and it was consistent with the shift from E1 toward E2 conformations [98]. However Grx1, which mediates deglutathionylation, co-immunoprecipitates with β1 subunits in myocytes lysate and may abolish oxidant induced Na+-K+ pump inhibition [93]. The increased interaction of Grx1 with the β1 subunit in E1 compared with E2 states may reflect a mechanism that prevents progressive amplification of E1-dependent β1 subunit glutathionylation and an excessive pump inhibition.

Because of the critical role of β1 glutathionylation in the inhibition of the Na+-K+ pump in the heart, Liu et al. [99] have recently investigated the oxidative inhibition of the vascular Na+-K+ pump via NADPH oxidase-dependent β1 glutathionylation. The authors show that Ang II inhibits the vascular pump by increasing β1 glutathionylation, and this is mediated by the activation of NADPH oxidase. Thus, redox-dependent pump inhibition may be significant also in the regulation of vascular tone.

4.1.5. Contractile Proteins Myosin

Myosin is sensitive to in vitro glutathionylation, and three potential sites of glutathione binding have been identified by MALDI-TOF analysis, two of them located on the myosin head [58]. Glutathionylation of myosin has an important impact on the protein structure, as documented by the lower fluorescence quantum yield of glutathionylated myosin and its increased susceptibility to the proteolytic cleavage. Myosin function is also sensitive to glutathionylation, which modulates its ATPase activity, depending on GSSG redox balance. Thus, like the phosphorylation/dephosphorylation cycle, glutathionylation may represent a mechanism by which glutathione modulates sarcomere functions depending on the tissue redox state, and myosin may constitute a muscle redox-sensor. α-Actin

α-actin is also particularly sensitive to binding of glutathione in isolated cardiac and skeletal myofibrils under conditions of oxidative stress [57]. The glutathionylation of α-cardiac actin occurs non-enzymatically, but via spontaneous oxidation of a cysteinyl residue to a cysteinyl sulfenic acid intermediary, a mechanism previously reported by Johansson and Lundberg for cytoskeletal β-actin [100] and by Dalle-Donne et al. [101] for rabbit skeletal muscle actin. By light scattering, it has been demonstrated that α-cardiac actin polymerized slower than the native protein, when glutathionylated in vitro. Thus, as for cytoskeletal β-actin [49,52,55] and for skeletal muscle actin [101], even β-actin could constitute a direct target for oxidative modification in human heart, and its glutathionylation may represent a mechanism by which glutathione can modulate sarcomere functions, depending on the redox state of the tissue.

In multiple models, including ischemia-reperfusion, increased oxidative stress results in the glutathionylation of sarcomeric actin. Pizarro and Ogut [102] examined the functional impact of glutathionylated actin on the interaction with myosin-S1. They found that substituting glutathionylated F-actin for unmodified F-actin reduced the maximum actomyosin-S1 ATPase, and this was accompanied by an increase in the activation energy of the steady-state ATPase. Measurement of steady-state binding did not suggest a large impact of actin glutathionylation on the binding to myosin-S1. However, transient binding and dissociation kinetics determined by stopped-flow methods demonstrated that although actin glutathionylation did not significantly alter the rate constant of myosin-S1 binding, there was a significant decrease in the rate of ATP-induced myosin-S1 detachment in the presence of ADP. These results suggest that actin glutathionylation may play a limited, but defined, role in the alteration of contractility following oxidative stress to the myocardium, particularly through a decrease in the actomyosin ATPase activity. Myosin Binding Protein C (MyBP-C)

Recently, Lovelock et al. [103] have reported a significant increase in the glutathionylation of cardiac myosin binding protein-C (MyBP-C) in animals with diastolic dysfunction. Their findings support the hypothesis that changes in cross-bridge kinetics correlate with MyBP-C S-glutathionylation and that this oxidative modification may be responsible for the changes in cardiac dynamics. MyBP-C may directly interact with actin in the thin filaments, resulting in increased cross-bridge kinetics [104]. Whatever the case, the modification by S-glutathionylation of one or more cysteine residues of MyBP-C likely alters the proximity of the cross-bridges to or their interactions with the thin filament. Troponin

Troponin I (TnI) in mammalian fast-twitch (type II) fibers can be readily S-glutathionylated, and this results in a large increase in the Ca2+ sensitivity of the contractile apparatus with no detectable change in maximum force [105]. Mammalian TnIf has three cysteine residues, but when TnIf is in the troponin complex with troponin C and troponin T, only Cys133 is accessible and reactive [106]. Thus, the S-glutathionylation of TnIf is only attributable to a link with Cys133. Noteworthy, Mollica et al. [105] found that moderate-intensity cycling exercise for 40 min led to an approximately four-fold increase in the S-glutathionylation of TnIf in the vastus lateralis muscle of human subjects. Given that S-glutathionylation of TnIf of human type II fibers was found, like in rat type II fibers, to result in a large increase in Ca2+ sensitivity, the authors concluded that S-glutathionylation of TnIf may influence muscle performance in exercising humans. Increasing the Ca2+ sensitivity of the contractile apparatus by glutathionylation could be of great benefit in countering factors occurring with normal exercise and causing muscle fatigue [107].

In addition to increase contractile Ca2+ sensitivity, S-Glutathionylation of TnIf also increases the peak twitch force and rate of force development to action potential stimulation [108]. Thus, the overall effects of the S-glutathionylation of TnIf are highly comparable to those occurring with the phosphorylation of myosin light chain 2 [109], with both causing similar sized increases in Ca2+ sensitivity and similar twitch force potentiation in fast-twitch muscle fibers, though by distinctly different mechanisms. However, if the activity continued for too long, other deleterious effects of the oxidants could antagonize and counter the potentiating effects of the S-glutathionylation of TnIf [110,111].

4.2. Myocardial Metabolism

4.2.1. Complex I (CI)

A wide range of mitochondrial membrane proteins contain exposed thiols that react with GSSG to form mixed disulfides, but a prominent target seems to be the respiratory chain enzyme, Complex I (CI) [13,112114]. In isolated cardiac mitochondria, CI is highly susceptible to glutathionylation under conditions of oxidative stress, showing a dose- and time-dependent inactivation after treatment with GSSG [115]. Furthermore, in cultured cardiomyocytes, CI activity was strongly inhibited after in vivo treatment with hydrogen peroxide [115]. CI represents the entry point of electrons into oxidative phosphorylation, making this enzyme particularly critical for cellular health [116]. CI glutathionylation leads to an increase of superoxide production, and, following de-glutathionylation, superoxide returns to basal levels. Within intact mitochondria, most of this superoxide produced after CI glutathionylation is converted to H2O2, which can then diffuse into the cytoplasm. By this mechanism, mitochondria may regulate redox signaling, and glutathione oxidation contributes to the pathological changes occurring during oxidative stress [13].

4.2.2. Complex II (CII)

In addition to CI, Chen et al. [9] have demonstrated that myocardial infarction leads to S-glutathionylation of Complex II (CII), confirmed ex vivo using a Langendorff system of ischemia and reperfusion. LC-MS/MS demonstrated S-glutathionylation on Cys-90 of purified CII. This modification enhances enzyme activity and reduces O2− production [9].

Mitochondrial targets for glutathionylation continue to accumulate, although most mitochondrial proteins are glutathionylated only transiently, and a smaller fraction is persistently glutathionylated [114]. CII requires a physiological glutathionylation to explicate its optimal function, thus representing an example of a protein that is persistently glutathionylated [9,117].

4.2.3. ATP synthase Complex (CV)

Furthermore, the mitochondrial ATP synthase complex undergoes a number of cysteine-specific oxidative modifications in the failing heart [118]. In particular, the authors found that the α-subunit of the ATP synthase Complex (CV) is glutathionylated in mitochondria isolated from dyssynchronous heart failure (DHF) and could be induced by GSSG in a dose-dependent manner. Interestingly, the levels of glutathionylated CV were partially normalized in cardiac resynchronization therapy (CRT), an effective clinical treatment for heart failure patients with conduction delay, impaired contraction and energetics.

4.2.4. Sirtuin-1

Sirtuins are a highly conserved family of histone/protein deacetylases and have been shown to participate in biological functions related to the development of heart failure, including regulation of energy production, oxidative stress, intracellular signaling, angiogenesis, autophagy and cell death/survival. Mammals possess seven sirtuins. Sirtuin 1 (Sirt-1) is an NAD+-dependent deacetylase located in the nucleus. In the vascular endothelium, Sirt-1 promotes cellular homeostasis through deacetylating a wide variety of targets, including eNOS, forkhead box transcription factor O1 (FOXO1) and p53 [119]. Sirt-1 activity depends on the availability of NAD+, such that increases in the [NAD+]/[NADH] ratio during caloric restriction activate the enzyme and can regulate gene expression and apoptosis. Using the purified protein, Zee et al. [120] demonstrated that nitrosoglutathione (GSNO) decreased Sirt-1 activity, and this effect was mediated by S-glutathionylation. The authors identified Cys67 as the site of S-glutathionylation by Linear Ion Trap-Orbitrap MS [120]. In addition, also Cys482 has been found to be modified by hydroxynonenal on MALDI-TOF-TOF analysis [121].

4.2.5. Aldose Reductase

Aldose reductase (alditol: NADP+ oxidoreductase, AR) is an aldehyde metabolizing enzyme that catalyzes the NADPH-dependent reduction of aldo sugars and a variety of aldehydes. Aldose reductase is an NADPH-dependent monomeric protein that belongs to the aldo-keto reductase superfamily [122,123]. The protein is expressed basally in many tissues, and its expression is enhanced by growth factors, such as fibroblast growth factor and platelet-derived growth factor [124], and by cytokines, such as tumor necrosis factor-α [125,126]. The enzyme is susceptible to covalent modification by several disulfides and thiol agents at Cys298[127129]. However, only GSSG was able to determine inactivation of the enzyme [130]. Its inhibition has been shown to increase oxidative injury and to abolish the late phase of ischemic preconditioning.

In the vasculature, aldose reductase mediates high-glucose-induced smooth muscle cell proliferation, and in cardiac tissue, it can modulate the late phase of ischemia reperfusion [131]. Rat hearts subjected to ischemia, in situ or ex vivo, display a 2–4-fold increase in AR activity. The AR activity was not further enhanced by reperfusion. In vivo, hearts subjected to ischemia reperfusion showed a two- to four-fold increase in aldose reductase activity, demonstrating that reactive oxygen species formed in the ischemic heart activate AR, and this occurred by modifying its cysteine residues to sulfenic acids. By MALDI-TOF MS, it has been found that aldose reductase was S-glutathionylated at Cys298 and Cys303[132,133]. The role of AR in myocardial metabolism during ischemia needs to be investigated in greater detail to fully assess the functional significance of the activation of this enzyme by redox modification of its cysteine residues.

4.2.6. Hemoglobin

The binding of glutathione to the Cys93 of the hemoglobin (Hb) beta chain has been known for more than 20 years and is associated with inhibition of Hb S-polymerization, increased oxygen affinity and a reduced alkaline Bohr effect [134,135]. At least three different types of glutathionylated Hb can exist in erythrocytes: a mixed disulfide bond between GSH and normal Hb; a disulfide bond between the Cys93 of the metHb beta chain and GSSG; and a disulfide bond between the other cysteine residues of metHb alpha chain and/or metHb beta chain and GSSG [136,137]. Recently, Metere et al. [138] found that, besides Cys93, Hb glutathionylation occurs also at Cys112 of the β-chain, providing a new potential GSH source hitherto unknown. They found that CO treatment of whole blood increases the GSH concentration in red blood cells cytosol, and this is linked to a significant Hb deglutathionylation. This process does not activate glycolytic metabolism, boosts the pentose phosphate pathway, increases glutathione reductase activity and decreases GSSG concentration, thus evidencing a CO signaling in human RBC driven by Hb glutathionylation. Hb is also a target for S-nitrosylation [139], and this modification may play a role in blood flow regulation [140,141]. Overall, these evidences made Hb a very useful marker of oxidative stress [142] and a good candidate in monitoring redox aspects of cardiovascular diseases. However, so far, neither the modification of Hb by glutathione nor by NO has been translated into effective treatments in such diseases.

4.3. Myocardial Proliferation and Hypertrophy


p21Ras is one major regulator in growth factor signaling in the vasculature. It is known to have four exposed redox-sensitive cysteines [143,144]. Adachi et al. [22] have demonstrated that angiotensin II-induced hypertrophy in vascular smooth muscle cells is regulated by the S-glutathionylation of p21Ras at Cys118. The GSH-adduct and the resulting activation of the p21Ras-MEK-ERK pathway were reversed by overexpression of catalase, glutaredoxin-1 or dominant negative p47Phox. In cardiac tissue, thioredoxin regulates pressure-overload-induced cardiac hypertrophy. Compared with wild-type animals, those without thioredoxin had greater cardiac hypertrophy, while overexpression of the protein resulted in attenuated cardiac size. The mechanism appeared to be due to modulation of p21Ras at Cys118, as demonstrated by in vitro models of strain and alpha-adrenergic receptor-stimulated cardiac hypertrophy in cardiomyocytes [145,146]. The modification of p21Ras likely occurs at Cys118 and supports a mechanism of p21Ras S-nitrosation, followed by an exchange reaction, which leaves p21Ras S-glutathionylated.

4.4. Myocardial Inflammation

4.4.1. NFkB

The transcription factor, NFkB, a central regulator of immunity, is subject to regulation by redox changes [147]. It controls transcription of a variety of genes that regulate immune responses and inflammation [2]. S-glutathionylation inhibits the NFkB pathway at multiple points, including p50 [148], RelA/p65 [149] and IKK-β [51]. NFkB itself is redox-regulated, and its DNA-binding activity can be reduced by oxidative stress and activated during hypoxia [16,149]. The interaction with its inhibitor (IkB) retains NFkB in the cytoplasm in a latent inactive heterodimeric form (p65:p50 or p50:cRel) [150,151]. Once activated, NFkB translocates to the nucleus, where it binds to DNA and activates various target genes [152]. In vivo Glrx gene deletion sensitizes cells to oxidative inactivation of IKK-β and dampens TNFα-induced IKK and NFkB activation, resulting in varied responses to inflammation [51].

Recent evidence suggests that signaling by the proinflammatory cytokine, interleukin-1β (IL-1 β), is dependent on ROS derived from NADPH oxidase [153]. Redox signaling in response to IL-1β is known to require endocytosis of its cognate receptor (IL-1R1), followed by the formation of redox-active endosomes containing NADPH oxidase 2 (Nox2) (also called redoxosomes) [154,155]. The consequent generation of ROS by redoxosomes is responsible for the downstream recruitment of IL-1R1 effectors (IRAK, TRAF6 and IkB kinase kinases) and, ultimately, for activation of NFkB.

4.4.2. Interferon Regulator Protein 3

Interferon regulatory factor 3 (IRF3) is an essential transcriptional regulator of the interferon genes. IRF3 is constitutively present in a latent conformation in the cell cytoplasm. Prinarakis et al. [156] reported that in human embryonic kidney (HEK) 293 cells, IRF3 is post-translationally modified by S-glutathionylation. Upon infection with Sendai virus, IRF3 undergoes deglutathionylation by the cytoplasmic enzyme, glutaredoxin-1 (GRX-1); it becomes phosphorylated, homodimerizes, translocates to the nucleus, binds to target genes and activates transcription by interacting with CBP/p300 co-activators. In virus-infected GRX-1 knockdown cells, phosphorylation, homodimerization and nuclear translocation of IRF3 do not occur; consequently, its transcriptional activity and the expression of interferon-β (IFNβ) are severely reduced. Taken together, these findings reveal a crucial role for S-glutathionylation in controlling the activation of IRF3 and IFNβ gene expression, with IRF3 deglutathionylation essential for transcriptional activation of the interferon genes.

5. Concluding Remarks

S-glutathionylation is a redox-dependent post-translational modification with growing relevance in signal transduction. Redox signals have been implicated in several physiological processes, including kinase signaling, channel function, apoptotic proteolysis and regulation of transcription; thus, S-glutathionylation may represent a “modulator” of these pathways that often cross-talk with each other. Similarly to phosphorylation, cysteine modification is critical to cellular signaling, and its deregulation has consequences over a number of human diseases, including cardiovascular diseases. Indeed, many proteins undergoing glutathionylation may contribute to the etiology of myocardial infarction, cardiac hypertrophy and atherosclerosis. In this review, we have illustrated tools and strategies to monitor protein S-glutathionylation and describe the proteins so far identified as glutathionylated in myocardial contraction, hypertrophy and inflammation.

6. Future Directions

Like the phosphorylation/dephosphorylation cycle, glutathionylation represents a mechanism by which glutathione modulates sarcomere functions depending on the tissue redox state. S-glutathionylation affects either phosphatases and/or kinases, thus potentially influencing phospho/dephosphorylation pathways and becoming a nexus between sulfur and phosphorous biochemistry. The cross-talk between glutathionylation and phosphorylation may be critical for the proper functioning of the cardiac proteins. The cardiac ryanodine receptor (RyR2), for instance, is regulated by direct phosphorylation at different sites by cAMP-dependent kinase (PKA) or calmodulin kinase II (CaMKII), and this increases the probability of the RyR2 channel to be open. Furthermore, SERCA2 is indirectly regulated by phosphorylation through the accessory protein, phospholamban (PLN), which binds to and inhibits SERCA2 when dephosphorylated. Even the Na+-K+ ATPase is regulated by the selective phosphorylation of phospholemman in isolated myocytes [157].

As advances in both the methodology and technology accelerate the study of glutathionylated proteins, the critical role they play in CVD is beginning to emerge. Thus, in perspective, these modifications, in combination with more standardized therapies, may offer new promise for drug development and may be used as biomarkers or predictors of cardiovascular pathology.

Ijms 14 20845f1 1024
Figure 1. S-glutathionylation cycle. Low pKa cysteine residues of proteins are targets for S-glutathionylation under oxidative stress conditions. The cysteine residue is first oxidized to form protein sulfenic acids through the formation of a protein cysteinyl radical. Sulfenic acids are highly unstable, undergoing further oxidation to sulfinic and sulfonic acids. Protein sulfonic acids are susceptible to degradation, whereas both cysteinyl radical and sulfenic acid can be conjugated to GSH to form glutathionylated proteins (PSSG). S-glutathionylation can be reversed by various enzymes, such as thioredoxin (Trx), glutaredoxin (Grx), protein disulfide isomerase (PDI) and glutathione transferase omega 1 (GSTO1-1).

Click here to enlarge figure

Figure 1. S-glutathionylation cycle. Low pKa cysteine residues of proteins are targets for S-glutathionylation under oxidative stress conditions. The cysteine residue is first oxidized to form protein sulfenic acids through the formation of a protein cysteinyl radical. Sulfenic acids are highly unstable, undergoing further oxidation to sulfinic and sulfonic acids. Protein sulfonic acids are susceptible to degradation, whereas both cysteinyl radical and sulfenic acid can be conjugated to GSH to form glutathionylated proteins (PSSG). S-glutathionylation can be reversed by various enzymes, such as thioredoxin (Trx), glutaredoxin (Grx), protein disulfide isomerase (PDI) and glutathione transferase omega 1 (GSTO1-1).
Ijms 14 20845f1 1024
Ijms 14 20845f2 1024
Figure 2. Quantification of total S-glutathionylated proteins. The first step of this method is the sample lysis or homogenization in non-reducing buffer containing N-ethylmaleimide (NEM) to eliminate free thiols. After this initial step, proteins were precipitated, resuspended and reduced. Protein-sulfhydryls or free glutathione formed after the reduction step was then derivatized with a fluorescence probe, and the fluorescence was measured by fluorometric analysis with or without prior HPLC separation.

Click here to enlarge figure

Figure 2. Quantification of total S-glutathionylated proteins. The first step of this method is the sample lysis or homogenization in non-reducing buffer containing N-ethylmaleimide (NEM) to eliminate free thiols. After this initial step, proteins were precipitated, resuspended and reduced. Protein-sulfhydryls or free glutathione formed after the reduction step was then derivatized with a fluorescence probe, and the fluorescence was measured by fluorometric analysis with or without prior HPLC separation.
Ijms 14 20845f2 1024
Ijms 14 20845f3 1024
Figure 3. Detection of glutathionylated proteins by 35S-cysteine labeling. The first step of radiolabeling of the glutathione pool is the inhibition of protein synthesis with cycloheximide, followed by incubation with 35S-cysteine. 35S-glutathione is then synthesized by the glutathione cycle. After the initial labeling step, the cells are placed under conditions of oxidative stress, leading to protein S-thiolation. Proteins are then extracted and separated on non-reducing mono- or bi-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis. S-thiolated proteins can be visualized by autoradiography, and the radioactive gel spot are excised and digested with trypsin. The resultant tryptic peptides are subjected to matrix-assisted laser desorption/ionization (MALDI-TOF) followed by database searching to identify S-glutathionylated proteins subjected to bottom-up proteomic analysis in order to identify S-glutathionylated proteins.

Click here to enlarge figure

Figure 3. Detection of glutathionylated proteins by 35S-cysteine labeling. The first step of radiolabeling of the glutathione pool is the inhibition of protein synthesis with cycloheximide, followed by incubation with 35S-cysteine. 35S-glutathione is then synthesized by the glutathione cycle. After the initial labeling step, the cells are placed under conditions of oxidative stress, leading to protein S-thiolation. Proteins are then extracted and separated on non-reducing mono- or bi-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis. S-thiolated proteins can be visualized by autoradiography, and the radioactive gel spot are excised and digested with trypsin. The resultant tryptic peptides are subjected to matrix-assisted laser desorption/ionization (MALDI-TOF) followed by database searching to identify S-glutathionylated proteins subjected to bottom-up proteomic analysis in order to identify S-glutathionylated proteins.
Ijms 14 20845f3 1024
Ijms 14 20845f4 1024
Figure 4. Detection of glutathionylated proteins by biotin labeling. Proteins are first alkylated with N-ethylmaleimide to block free sulfhydryls. Oxidized sulfhydryls are then reduced with Grx3 and labeled with biotin. Biotin-labeled proteins are affinity purified on avidin-conjugated agarose beads. After extensive washing with detergent buffer, proteins bound to avidin via a mixed disulfide bond with biotinylated glutathione can be eluted by incubation with reducing agents (DTT or β-mercaptoethanol), separated on two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (2D SDS PAGE) and subjected to proteomic analysis.

Click here to enlarge figure

Figure 4. Detection of glutathionylated proteins by biotin labeling. Proteins are first alkylated with N-ethylmaleimide to block free sulfhydryls. Oxidized sulfhydryls are then reduced with Grx3 and labeled with biotin. Biotin-labeled proteins are affinity purified on avidin-conjugated agarose beads. After extensive washing with detergent buffer, proteins bound to avidin via a mixed disulfide bond with biotinylated glutathione can be eluted by incubation with reducing agents (DTT or β-mercaptoethanol), separated on two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (2D SDS PAGE) and subjected to proteomic analysis.
Ijms 14 20845f4 1024

Conflicts of Interest

The authors declare no conflict of interest.


  1. Elahi, M.M.; Kong, Y.X.; Matata, B.M. Oxidative stress as a mediator of cardiovascular disease. Oxid. Med. Cell Longev 2009, 2, 259–269. [Google Scholar]
  2. Mieyal, J.J.; Gallogly, M.M.; Qanungo, S.; Sabens, E.A.; Shelton, M.D. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid. Redox Signal 2008, 10, 1941–1988. [Google Scholar]
  3. Pimentel, D.; Haeussler, D.J.; Matsui, R.; Burgoyne, J.R.; Cohen, R.A.; Bachschmid, M.M. Regulation of cell physiology and pathology by protein S-glutathionylation: Lessons learned from the cardiovascular system. Antioxid. Redox Signal 2012, 16, 524–42. [Google Scholar]
  4. Kumar, V.; Calamaras, T.D.; Haeussler, D.; Colucci, W.S.; Cohen, R.A.; McComb, M.E.; Pimentel, D.; Bachschmid, M.M. Cardiovascular redox and ox stress proteomics. Antioxid. Redox Signal 2012, 17, 1528–1559. [Google Scholar]
  5. Kim, G.H.; Ryan, J.J.; Archer, S.L. The role of redox signaling in epigenetics and cardiovascular disease. Antioxid. Redox Signal 2013, 18, 1920–1936. [Google Scholar]
  6. Eaton, P.; Wright, N.; Hearse, D.J.; Shattock, M.J. Glyceraldehyde phosphate dehydrogenase oxidation during cardiac ischemia and reperfusion. J. Mol. Cell. Cardiol 2002, 34, 1549–1560. [Google Scholar]
  7. Chen, F.C.; Ogut, O. Decline of contractility during ischemia-reperfusion injury: Actin glutathionylation and its effect on allosteric interaction with tropomyosin. Am. J. Physiol. Cell. Physiol 2006, 290, C719–C727. [Google Scholar]
  8. Wang, J.; Boja, E.S.; Tan, W.; Tekle, E.; Fales, H.M.; English, S.; Mieyal, J.J.; Chock, P.B. Reversible glutathionylation regulates actin polymerization in A431 cells. J. Biol. Chem 2001, 276, 47763–47766. [Google Scholar]
  9. Chen, Y.R.; Chen, C.L.; Pfeiffer, D.R.; Zweier, J.L. Mitochondrial complex II in the post-ischemic heart: Oxidative injury and the role of protein S-glutathionylation. J. Biol. Chem 2007, 282, 32640–32654. [Google Scholar]
  10. Malik, G.; Nagy, N.; Ho, Y.S.; Maulik, N.; Das, D.K. Role of glutaredoxin-1 in cardioprotection: An insight with Glrx1 transgenic and knockout animals. J. Mol. Cell Cardiol 2008, 44, 261–269. [Google Scholar]
  11. Nagy, N.; Malik, G.; Tosaki, A.; Ho, Y.S.; Maulik, N.; Das, D.K. Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis. J. Mol. Cell Cardiol 2008, 44, 252–260. [Google Scholar]
  12. Mukherjee, S.; Gangopadhyay, H.; Das, D.K. Broccoli: A unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily. J. Agric. Food Chem 2008, 56, 609–617. [Google Scholar]
  13. Taylor, E.R.; Hurrell, F.; Shannon, R.J.; Lin, T.K.; Hirst, J.; Murphy, M.P. Reversible glutathionylation of Complex I increases mitochondrial superoxide formation. J. Biol. Chem 2003, 278, 19603–19610. [Google Scholar]
  14. Heineke, J.; Molkentin, J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol 2006, 7, 589–600. [Google Scholar]
  15. Pimentel, D.R; Adachi, T.; Ido, Y.; Heibeck, T.; Jiang, B.; Lee, Y.; Melendez, J.A.; Cohen, R.A.; Colucci, W.S. Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation. J. Mol. Cell Cardiol 2006, 41, 613–22. [Google Scholar]
  16. Pantano, C.; Reynaert, N.L.; Van Der Vliet, A.; Janssen-Heininger, Y.M.W. Redox-sensitive kinases of the nuclear factor-kB signaling pathway. Antioxid. Redox Signal 2006, 8, 1791–1806. [Google Scholar]
  17. Wang, Y.; Qiao, M.; Mieyal, J.J.; Asmis, L.M.; Asmis, R. Molecular mechanism of glutathione-mediated protection from oxidized low-density lipoprotein-induced cell injury in human macrophages: Role of glutathione reductase and glutaredoxin. Free Radic. Biol. Med 2006, 41, 775–785. [Google Scholar]
  18. Okuda, M.; Inoue, N.; Azumi, H.; Seno, T.; Sumi, Y.; Hirata, K.; Kawashima, S.; Hayashi, Y.; Itoh, H.; Yodoi, J.; Yokoyama, M. Expression of glutaredoxin in human coronary arteries: Its potential role in antioxidant protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol 2001, 21, 1483–1487. [Google Scholar]
  19. Kher, N.; Marsh, J.D. Pathobiology of atherosclerosis—A brief review. Semin. Thromb. Hemost 2004, 30, 665–672. [Google Scholar]
  20. Nonaka, K.; Kume, N.; Urata, Y.; Seto, S.; Kohno, T.; Honda, S.; Ikeda, S.; Muroya, T.; Ikeda, Y.; Ihara, Y.; Kita, T.; Kondo, T. Serum levels of S-glutathionylated proteins as a risk marker for arteriosclerosis obliterans. Circ. J 2007, 71, 100–105. [Google Scholar]
  21. Adachi, T.; Weisbrod, R.M.; Pimentel, D.R.; Ying, J.; Sharov, V.S.; Schoneich, C.; Cohen, R.A. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat. Med 2004, 10, 1200–1207. [Google Scholar]
  22. Adachi, T.; Pimentel, D.R.; Heibeck, T.; Hou, X.; Lee, Y.J.T.; Jiang, B.; Cohen, R.A. S-glutathiolation of Ras mediates redox-sensitive signaling by Angiotensin ii in vascular smooth muscle cells. J. Biol. Chem 2004, 279, 29857–29862. [Google Scholar]
  23. Landmesser, U.; Cai, H.; Dikalov, S.; McCann, L.; Hwang, J.; Jo, H.; Holland, S.M.; Harrison, D.G. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40, 511–515. [Google Scholar]
  24. Wang, H.D.; Xu, S.; Johns, D.G.; Du, Y.; Quinn, M.T.; Cayatte, A.J.; Cohen, R.A. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ. Res 2001, 88, 947–953. [Google Scholar]
  25. Clavreul, N.; Adachi, T.; Pimental, D.R.; Ido, Y.; Schoneich, C.; Cohen, R.A. S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells. FASEB J 2006, 20, 518–520. [Google Scholar]
  26. Wang, J.; Pan, S.; Berk, B.C. Glutaredoxin mediates Akt and eNOS activation by flow in a glutathione reductase dependent manner. Arterioscler. Thromb. Vasc.Biol 2007, 27, 1283–1288. [Google Scholar]
  27. Mullonkal, C.J.; Toledo-Pereyra, L.H. Akt in ischemia and reperfusion. J. Invest. Surg 2007, 20, 195–203. [Google Scholar]
  28. Dixon, W.G.; Symmons, D.P. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann. Rheum. Dis 2007, 66, 1132–1136. [Google Scholar]
  29. Pan, S.; Berk, B.C. Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: Key role for glutaredoxin in the death pathway. Circ. Res 2007, 100, 213–219. [Google Scholar]
  30. Thomas, J.A.; Zhao, W.; Hendrich, S.; Haddock, P. Analysis of cells and tissues for S-thiolation of specific proteins. Methods Enzymol 1995, 251, 423–429. [Google Scholar]
  31. Dalle-Donne, I.; Milzani, A.; Gagliano, N.; Colombo, R.; Giustarini, D.; Rossi, R. Molecular mechanisms and potential clinical significance of S-glutathionylation. Antioxid. Redox Signal 2008, 10, 445–473. [Google Scholar]
  32. Lu, J.; Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med 2013. in press. [Google Scholar]
  33. Findlay, V.J.; Townsend, D.M.; Morris, T.E.; Fraser, J.P.; He, L.; Tew, K.D. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res 2006, 66, 6800–6806. [Google Scholar]
  34. Menon, D.M; Board,, P.G. A role for glutathione transferase omega 1 (GSTO1–1) in the glutathionylation cycle. J. Biol. Chem 2013, 288, 25769–25779. [Google Scholar]
  35. Tew, K.D.; Townsend, D.M. Redox platforms in cancer drug discovery and development. Curr. Opin. Chem. Biol 2011, 15, 156–161. [Google Scholar]
  36. Ansong, C.; Wu, S.; Meng, D.; Liu, X.; Brewer, H.M.; Deatherage Kaiser, B.L.; Nakayasu, E.S.; Cort, J.R.; Pevzner, P.; Smith, R.D.; et al. Top-down proteomics reveals a unique protein S-thiolation switch in Salmonella Typhimurium in response to infection-like conditions. Proc. Natl. Acad. Sci. USA 2013, 25, 10153–10158. [Google Scholar]
  37. Townsend, D.M.; Manevich, Y.; He, L.; Hutchens, S.; Pazoles, C.J.; Tew, K.D. Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress. J. Biol. Chem 2009, 284, 436–345. [Google Scholar]
  38. Pastore, A.; Martinelli, D.; Piemonte, F.; Tozzi, G.; Boenzi, S.; Di Giovamberardino, G.; Petrillo, S.; Bertini, E.; Dionisi-Vici, C. Glutathione metabolism in cobalamin deficiency type C (cblC). J. Inherit. Metab. Dis 2013. in press. [Google Scholar]
  39. Petrillo, S.; Piemonte, F.; Pastore, A.; Tozzi, G.; Aiello, C.; Pujol, A.; Cappa, M.; Bertini, E. Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Mol. Genet. Metab 2013, 109, 366–370. [Google Scholar]
  40. Pastore, A.; Petrillo, S.; Tozzi, G.; Carrozzo, R.; Martinelli, D.; Dionisi-Vici, C.; Di Giovamberardino, G.; Ceravolo, F.; Klein, M.B.; Miller, G.; et al. Glutathione: A redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies. Mol. Genet. Metab 2013, 109, 208–214. [Google Scholar]
  41. Menon, D.; Board, P.G. A fluorometric method to quantify protein glutathionylation using glutathione derivatization with 2,3-naphthalenedicarboxaldehyde. Anal. Biochem 2013, 433, 132–136. [Google Scholar]
  42. Lind, C.; Gerdes, R.; Schuppe-Koistinen, I.; Cotgreave, I.A. Studies on the mechanism of oxidative modification of human glyceraldehyde-3-phosphate dehydrogenase by glutathione: Catalysis by glutaredoxin. Biochem. Biophys. Res. Commun 1998, 247, 481–486. [Google Scholar]
  43. Ward, N.E.; Stewart, J.R.; Ioannides, C.G.; O’Brian, C.A. Oxidant-induced S-glutathiolation inactivates protein kinase C-alpha (PKC-alpha): A potential mechanism of PKC isozyme regulation. Biochemistry 2000, 39, 10319–10329. [Google Scholar]
  44. Manevich, Y.; Feinstein, S.I.; Fisher, A.B. Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. Proc. Natl. Acad. Sci. USA 2004, 101, 3780–3785. [Google Scholar]
  45. Hidalgo, C.; Sanchez, G.; Barrientos, G.; Aracena-Parks, P. A transverse tubule NADPH oxidase activity stimulates calcium release from isolated triads via ryanodine receptor type 1 S-glutathionylation. J. Biol. Chem 2006, 281, 26473–26482. [Google Scholar]
  46. Rokutan, K.; Thomas, J.A.; Johnston, R.B., Jr. Phagocytosis and stimulation of the respiratory burst by phorbol diester initiate S-thiolation of specific proteins in macrophages. J. Immunol 1991, 147, 260–264. [Google Scholar]
  47. Ravichandran, V.; Seres, T.; Moriguchi, T.; Thomas, J.A.; Johnston, R.B., Jr. S-thiolation of glyceraldehyde-3-phosphate dehydrogenase induced by the phagocytosis-associated respiratory burst in blood monocytes. J. Biol. Chem 1994, 269, 25010–25015. [Google Scholar]
  48. Seres, T.; Ravichandran, V.; Moriguchi, T.; Rokutan, K.; Thomas, J.A.; Johnston, R.B., Jr. Protein S-thiolation and dethiolation during the respiratory burst in human monocytes: A reversible post-translational modification with potential for buffer ring the effects of oxidant stress. J. Immunol 1996, 156, 1973–1980. [Google Scholar]
  49. Fratelli, M.; Demol, H.; Puype, M.; Casagrande, S.; Eberini, I.; Salmona, M.; Bonetto, V.; Mengozzi, M.; Duffieux, F.; Miclet, E.; et al. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc. Natl. Acad. Sci. USA 2002, 99, 3505–3510. [Google Scholar]
  50. Brennan, J.P.; Miller, J.I.; Fuller, W.; Wait, R.; Begum, S.; Dunn, M.J.; Eaton, P. The utility of N,N-biotinyl glutathione disulfide in the study of protein S-glutathiolation. Mol. Cell. Proteomics 2006, 5, 215–225. [Google Scholar]
  51. Reynaert, N.L.; Van der Vliet, A.; Guala, A.S.; McGovern, T.; Hristova, M.; Pantano, C.; Heintz, N.H.; Heim, J.; Ho, Y.S.; Matthews, D.E.; et al. Dynamic redox control of NF-kappaB through glutaredoxin regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc. Natl. Acad. Sci. USA 2006, 103, 13086–13091. [Google Scholar]
  52. Dalle-Donne, I.; Giustarini, D.; Rossi, R.; Colombo, R.; Milzani, A. Reversible S-glutathionylation of Cys374 regulates actin filament formation by inducing structural changes in the actin molecule. Free Radic. Biol. Med 2003, 34, 23–32. [Google Scholar]
  53. Wang, J.; Tekle, E.; Oubrahim, H.; Mieyal, J.J.; Stadtman, E.R.; Chock, P.B. Stable and controllable RNA interference: Investigating the physiological function of glutathionylated actin. Proc. Natl. Acad. Sci. USA 2003, 100, 5103–5106. [Google Scholar]
  54. Pastore, A.; Tozzi, G.; Gaeta, L.M.; Bertini, E.; Serafini, V.; Di Cesare, S.; Bonetto, V.; Casoni, F.; Carrozzo, R.; Federici, G.; et al. Actin glutathionylation increases in fibroblasts of patients with Friedreich’s ataxia: A potential role in the pathogenesis of the disease. J. Biol. Chem 2003, 43, 42588–42595. [Google Scholar]
  55. Fiaschi, T.; Cozzi, G.; Raugei, G.; Formigli, L.; Ramponi, G.; Chiarugi, P. Redox regulation of beta-actin during integrin-mediated cell adhesion. J. Biol. Chem 2006, 281, 22983–22991. [Google Scholar]
  56. Sparaco, M.; Gaeta, L.M.; Tozzi, G.; Bertini, E.; Pastore, A.; Simonati, A.; Santorelli, F.M.; Piemonte, F. Protein glutathionylation in human central nervous system: Potential role in redox regulation of neuronal defense against free radicals. J. Neurosci. Res 2006, 83, 256–263. [Google Scholar]
  57. Passarelli, C.; Di Venere, A.; Piroddi, N.; Pastore, A.; Scellini, B.; Tesi, C.; Petrini, S.; Sale, P.; Bertini, E.; Poggesi, C.; et al. Susceptibility of isolated myofibrils to in vitro glutathionylation: potential relevance to muscle functions. Cytoskeleton 2010, 67, 81–89. [Google Scholar]
  58. Passarelli, C.; Petrini, S.; Pastore, A.; Bonetto, V.; Sale, P.; Gaeta, L.M.; Tozzi, G.; Bertini, E.; Canepari, M.; Rossi, R.; et al. Myosin as a potential redox-sensor: An in vitro study. J. Muscle Res. Cell. Motil 2008, 29, 119–126. [Google Scholar]
  59. Landino, L.M.; Robinson, S.H.; Skreslet, T.E.; Cabral, D.M. Redox modulation of tau and microtubule-associated protein-2 by the glutathione/glutaredoxin reductase system. Biochem. Biophys. Res. Commun 2004, 323, 112–117. [Google Scholar]
  60. Fernandes, A.P.; Fladvad, M.; Berndt, C.; Andresen, C.; Lillig, C.H.; Neubauer, P.; Sunnerhagen, M.; Holmgren, A.; Vlamis-Gardikas, A. A novel monothiol glutaredoxin (Grx4) from Escherichia coli can serve as a substrate for thioredoxin reductase. J. Biol. Chem 2005, 280, 24544–24552. [Google Scholar]
  61. Hoppe, G.; Chai, Y.C.; Crabb, J.W.; Sears, J. Protein S-glutathionylation in retinal pigment epithelium converts heat shock protein 70 to an active chaperone. Exp. Eye Res 2004, 78, 1085–1092. [Google Scholar]
  62. West, M.B.; Hill, B.G.; Xuan, Y.T.; Bhatnagar, A. Protein glutathiolation by nitric oxide: An intracellular mechanism regulating redox protein modification. FASEB J 2006, 20, 1715–1717. [Google Scholar]
  63. Aracena, P.; Tang, W.; Hamilton, S.L.; Hidalgo, C. Effects of S-glutathionylation and S-nitrosylation on calmodulin binding to triads and FKBP12 binding to type 1 calcium release channels. Antioxid. Redox Signal 2005, 7, 870–881. [Google Scholar]
  64. Aracena-Parks, P.; Goonasekera, S.A.; Gilman, C.; Dirksen, R.T.; Hidalgo, C.; Hamilton, S.L. Identification of cysteines involved in S-nitrosylation, S-glutathionylation, and oxidation to disulfides in RyR1. J. Biol. Chem 2006, 281, 40354–40368. [Google Scholar]
  65. Craghill, J.; Cronshaw, A.D.; Harding, J.J. The identification of a reaction site of glutathione mixed-disulphide formation on cS-crystallin in human lens. Biochem. J 2004, 379, 595–600. [Google Scholar]
  66. Newman, S.F.; Sultana, R.; Perluigi, M.; Coccia, R.; Cai, J.; Pierce, W.M.; Klein, J.B.; Turner, D.M.; Butterfield, D.A. An increase in S-glutathionylated proteins in the Alzheimer’s disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res 2007, 85, 1506–1514. [Google Scholar]
  67. Townsend, D.M.; Findlay, V.L.; Fazilev, F.; Ogle, M.; Fraser, J.; Saavedra, J.E.; Ji, X.; Keefer, L.K.; Tew, K.D. A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with Sglutathionylation of proteins. Mol. Pharmacol 2006, 69, 501–508. [Google Scholar]
  68. Lampela, O.; Juffer, A.H.; Rauk, A. Conformational analysis of glutathione in aqueous solution with molecular dynamics. J. Phys. Chem. A 2003, 107, 9208–9220. [Google Scholar]
  69. Smith, L.M.; Kelleher, N.L. Consortium for Top Down Proteomics. Proteoform: A single term describing protein complexity. Nat. Methods 2013, 10, 186–187. [Google Scholar]
  70. Niture, S.K.; Velu, C.S.; Bailey, N.I.; Srivenugopal, K.S. S-thiolation mimicry: Quantitative and kinetic analysis of redox status of protein cysteines by glutathione-affinity chromatography. Arch. Biochem. Biophys 2005, 444, 174–184. [Google Scholar]
  71. Velu, C.S.; Niture, S.K.; Doneanu, C.E.; Pattabiraman, N.; Srivenugopal, K.S. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 2007, 46, 7765–7780. [Google Scholar]
  72. Naito, C.; Kajita, M.; Niwa, T. Determination of glutathionyl hemoglobin in hemodialysis patients using electrospray ionization liquid chromatography-mass spectrometry. J. Chromatogr. B 1999, 731, 121–124. [Google Scholar]
  73. Pastore, A.; Mozzi, A.F.; Tozzi, G.; Gaeta, L.M.; Federici, G.; Bertini, E.; Lo Russo, A.; Mannucci, L.; Piemonte, F. Determination of glutathionyl-hemoglobin in human erythrocytes by cation-exchange high-performance liquid chromatography. Anal. Biochem 2003, 312, 85–90. [Google Scholar]
  74. Sun, C.; Shi, Z.Z.; Zhou, X.; Chen, L.; Zhao, X.M. Prediction of S-glutathionylation sites based on protein sequences. PLoS One 2013, 8, e55512. [Google Scholar]
  75. Sanchez, G.; Pedrozo, Z.; Domenech, R.J.; Hidalgo, C.; Donoso, P. Tachycardia increases NADPH oxidase activity and RyR2 S-glutathionylation in ventricular muscle. J. Mol. Cell Cardiol 2005, 39, 982–991. [Google Scholar]
  76. Sanchez, G.; Escobar, M.; Pedrozo, Z.; Macho, P.; Domenech, R.; Hartel, S.; Hidalgo, C.; Donoso, P. Exercise and tachycardia increase NADPH oxidase and ryanodine receptor-2 activity: Possible role in cardioprotection. Cardiovasc. Res 2008, 77, 380–386. [Google Scholar]
  77. Heumuller, S.; Wind, S.; Barbosa-Sicard, E.; Schmidt, H.H.; Busse, R.; Schroder, K.; Brandes, R.P. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008, 51, 211–217. [Google Scholar]
  78. Donoso, P.; Sanchez, G.; Bull, R.; Hidalgo, C. Modulation of cardiac ryanodine receptor activity by ROS and RNS. Front. Biosci 2011, 16, 553–567. [Google Scholar]
  79. Vangheluwe, P.; Raeymaekers, L.; Dode, L.; Wuytack, F. Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: Cell biological implications. Cell Calcium 2005, 38, 291–302. [Google Scholar]
  80. Vangheluwe, P.; Louch, W.E.; Ver Heyen, M.; Sipido, K.; Raeymaekers, L.; Wuytack, F. Ca2+ transport ATPase isoforms SERCA2a and SERCA2b are targeted to the same sites in the murine heart. Cell Calcium 2003, 34, 457–464. [Google Scholar]
  81. Cohen, R.A.; Adachi, T. Nitric-oxide-induced vasodilatation: Regulation by physiologic S-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc. Med 2006, 16, 109–114. [Google Scholar]
  82. Lock, J.T.; Sinkins, W.G.; Schilling, W.P. Effect of protein S-glutathionylation on Ca2+ homeostasis in cultured aortic endothelial cells. Am. J. Physiol. Heart Circ. Physiol 2011, 300, 493–506. [Google Scholar]
  83. Lancel, S.; Zhang, J.; Evangelista, A.; Trucillo, M.P.; Tong, X.; Siwik, D.A.; Cohen, R.A.; Colucci, W.S. Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ. Res 2009, 104, 720–723. [Google Scholar]
  84. Chen, C.A.; Wang, T.Y.; Varadharaj, S.; Reyes, L.A.; Hemann, C.; Talukder, M.A.; Chen, Y.R.; Druhan, L.J.; Zweier, J.L. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468, 1115–1118. [Google Scholar]
  85. Zweier, J.L.; Chen, C.A.; Druhan, L.J. S-glutathionylation reshapes our understanding of endothelial nitric oxide synthase uncoupling and nitric oxide/reactive oxygen species-mediated signaling. Antioxid. Redox Signal 2011, 14, 1769–1775. [Google Scholar]
  86. Kaplan, J.H. Biochemistry of Na, K-ATPase. Annu. Rev.Biochem 2002, 71, 511–535. [Google Scholar]
  87. Galougahi, K.K.; Liu, C.C.; Garcia, A.; Fry, N.A.; Hamilton, E.J.; Rasmussen, H.H.; Figtree, G.A. Protein kinase-dependent oxidative regulation of the cardiac Na+-K+ pump: Evidence from in vivo and in vitro modulation of cell signaling. J. Physiol 2013, 591, 2999–3015. [Google Scholar]
  88. Jorgensen, P.L.; Hakansson, K.O.; Karlish, S.J. Structure and mechanism of Na, K-ATPase: Functional sites and their interactions. Annu. Rev. Physiol 2003, 65, 817–849. [Google Scholar]
  89. Pieske, B.; Houser, S.R. [Na+], handling in the failing human heart. Cardiovasc. Res 2003, 57, 874–886. [Google Scholar]
  90. Pogwizd, S.M.; Sipido, K.R.; Verdonck, F.; Bers, D.M. Intracellular Na in animal models of hypertrophy and heart failure: Contractile function and arrhythmogenesis. Cardiovasc. Res 2003, 57, 887–896. [Google Scholar]
  91. Rasmussen, H.H.; Hamilton, E.J.; Liu, C.C.; Figtree, G.A. Reversible oxidative modification: Implications for cardiovascular physiology and pathophysiology. Trends Cardiovasc. Med 2010, 20, 85–90. [Google Scholar]
  92. Shimon, M.B.; Goldshleger, R.; Karlish, S.J. Specific Cu2+-catalyzed oxidative cleavage of Na, K-ATPase at the extracellular surface. J. Biol. Chem 1998, 273, 34190–34195. [Google Scholar]
  93. Figtree, G.A.; Rasmussen, H.H.; Liu, C.C. Oxidative regulation of the Na+ -K+ pump in cardiac physiology and pathology: Clarifying the published evidence. Circ. Res 2013, 112, 1. [Google Scholar]
  94. Liu, C.C.; Garcia, A.; Mahmmoud, Y.A.; Hamilton, E.J.; Galougahi, K.K.; Fry, N.A.; Figtree, G.A.; Cornelius, F.; Clarke, R.J.; Rasmussen, H.H. Susceptibility of β1 Na+-K+ pump subunit to glutathionylation and oxidative inhibition depends on conformational state of pump. J. Biol. Chem 2012, 287, 12353–12364. [Google Scholar]
  95. Morth, J.P.; Pedersen, B.P.; Toustrup-Jensen, M.S.; Sørensen, T.L.; Petersen, J.; Andersen, J.P.; Vilsen, B.; Nissen, P. Crystal structure of the sodium-potassium pump. Nature 2007, 450, 1043–1049. [Google Scholar]
  96. Shinoda, T.; Ogawa, H.; Cornelius, F.; Toyoshima, C. Crystal structure of the sodium-potassium pump at 2.4 A resolution. Nature 2009, 459, 446–450. [Google Scholar]
  97. Morth, J.P.; Pedersen, B.P.; Buch-Pedersen, M.J.; Andersen, J.P.; Vilsen, B.; Palmgren, M.G.; Nissen, P. A structural overview of the plasma membrane Na+, K+-ATPase and H+ATPase ion pumps. Nat. Rev. Mol. Cell Biol 2011, 12, 60–70. [Google Scholar]
  98. Dempski, R.E.; Hartung, K.; Friedrich, T.; Bamberg, E. Fluorometric measurements of intermolecular distances between the alpha- and beta-subunits of the Na+/K+-ATPase. J. Biol. Chem 2006, 281, 36338–36346. [Google Scholar]
  99. Liu, C.C.; Karimi Galougahi, K.; Weisbrod, R.M.; Hansen, T.; Ravaie, R.; Nunez, A.; Liu, Y.B.; Fry, N.; Garcia, A.; Hamilton, E.J.; et al. Oxidative inhibition of the vascular Na(+)-K(+) pump via NADPH oxidase-dependent β(1)-subunit glutathionylation: Implications for angiotensin II-induced vascular dysfunction. Free Radic. Biol. Med 2013, 65, 563–572. [Google Scholar]
  100. Johansson, M.; Lundberg, M. Glutathionylation of beta-actin via a cysteinyl sulfenic acid intermediary. Biochemistry 2007, 8, 26–32. [Google Scholar]
  101. Dalle-Donne, I.; Rossi, R.; Giustarini, D.; Colombo, R.; Milzani, A. Actin S-glutathionylation: Evidence against a thiol-disulphide exchange mechanism. Free Rad. Biol. Med 2003, 35, 1185–1193. [Google Scholar]
  102. Pizarro, G.O.; Ogut, O. Impact of actin glutathionylation on the actomyosin-S1 ATPase. Biochemistry 2009, 48, 7533–7538. [Google Scholar]
  103. Lovelock, J.D.; Monasky, M.M.; Jeong, E.M.; Lardin, H.A.; Liu, H.; Patel, B.G.; Taglieri, D.M.; Gu, L.; Kumar, P.; Pokhrel, N.; et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ. Res 2012, 110, 841–850. [Google Scholar]
  104. Harris, S.P.; Lyons, R.G.; Bezold, K.L. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ. Res 2011, 108, 751–764. [Google Scholar]
  105. Mollica, J.P.; Dutka, T.L.; Merry, T.L.; Lamboley, C.R.; McConell, G.K.; McKenna, M.J.; Murphy, R.M.; Lamb, G.D. S-glutathionylation of troponin I (fast) increases contractile apparatus Ca2+ sensitivity in fast-twitch muscle fibres of rats and humans. J. Physiol 2012, 590, 1443–1463. [Google Scholar]
  106. Chong, P.C.; Hodges, R.S. Proximity of sulfhydryl groups to the sites of interaction between components of the troponin complex from rabbit skeletal muscle. J. Biol. Chem 1982, 257, 2549–2555. [Google Scholar]
  107. Allen, D.G.; Lamb, G.D.; Westerblad, H. Skeletal muscle fatigue: Cellular mechanisms. Physiol. Rev 2008, 88, 287–332. [Google Scholar]
  108. Dutka, T.L.; Mollica, J.P.; Posterino, G.S.; Lamb, G.D. Modulation of contractile apparatus Ca2+ sensitivity and disruption of excitation-contraction coupling by S-nitrosoglutathione in rat muscle fibres. J. Physiol 2011, 589, 2181–2196. [Google Scholar]
  109. Stull, J.T.; Kamm, K.E.; Vandenboom, R. Myosin light chain kinase and the role of myosin light chain phosphorylation in skeletal muscle. Arch. Biochem. Biophys 2011, 510, 120–128. [Google Scholar]
  110. Andrade, F.H.; Reid, M.B.; Allen, D.G.; Westerblad, H. Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse. J. Physiol 1998, 509, 565–575. [Google Scholar]
  111. Lamb, G.D.; Westerblad, H. Acute effects of reactive oxygen and nitrogen species on the contractile function of skeletal muscle. J. Physiol 2011, 589, 2119–2127. [Google Scholar]
  112. Beer, S.M.; Taylor, E.R.; Brown, S.E.; Dahm, C.C.; Costa, N.J.; Runswick, M.J.; Murphy, M.P. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: Implications for mitochondrial redox regulation and antioxidant defense. J. Biol. Chem 2004, 279, 47939–47951. [Google Scholar]
  113. Hurd, T.R.; Requejo, R.; Filipovska, A.; Brown, S.; Prime, T.A.; Robinson, A.J.; Fearnley, I.M.; Murphy, M.P. Complex I within oxidatively stressed bovine heart mitochondria is glutathionylated on Cys-531 and Cys-704 of the 75-kDa subunit. J. Biol. Chem 2008, 283, 24801–24815. [Google Scholar]
  114. Kang, P.T.; Zhang, L.; Chen, C.L.; Chen, J.; Green, K.B.; Chen, Y.R. Protein thiyl radical mediates S-glutathionylation of complex I. Free Radic. Biol. Med 2012, 53, 962–973. [Google Scholar]
  115. Passarelli, C.; Tozzi, G.; Pastore, A.; Bertini, E.; Piemonte, F. GSSG-mediated Complex I defect in isolated cardiac mitochondria. Int. J. Mol. Med 2010, 26, 95–99. [Google Scholar]
  116. Papa, S.; De Rasmo, D.; Scacco, S.; Signorile, A.; Technikova-Dobrova, Z.; Palmisano, G.; Sardanelli, A.M.; Papa, F.; Panelli, D.; Scaringi, R.; et al. Mammalian Complex I: A regulable and vulnerable pacemaker in mitochondrial respiratory function. Biochim. Biophys. Acta 2008, 1777, 719–728. [Google Scholar]
  117. Zhang, L.; Kang, P.T.; Chen, C.L.; Green, K.B.; Chen, Y.R. Oxidative modifications of mitochondria complex II. Methods Mol. Biol 2013, 1005, 143–56. [Google Scholar]
  118. Wang, S.B.; Foster, D.B.; Rucker, J.; O’Rourke, B.; Kass, D.A.; Van Eyk, J.E. Redox regulation of mitochondrial ATP synthase: Implications for cardiac resynchronization therapy. Circ. Res 2011, 109, 750–757. [Google Scholar]
  119. Lee, I.H.; Cao, L.; Mostoslavsky, R.; Lombard, D.B.; Liu, J; Bruns, N.E.; Tsokos, M.; Alt, F.W.; Finkel, T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc. Natl. Acad. Sci. USA 2008, 105, 3374–3379. [Google Scholar]
  120. Zee, R.S.; Yoo, C.B.; Pimentel, D.R.; Perlman, D.H.; Burgoyne, J.R.; Hou, X.; McComb, M.E.; Costello, C.E.; Cohen, R.A.; Bachschmid, M.M. Redox regulation of sirtuin-1 by Sglutathiolation. Antioxid. Redox Signal 2010, 13, 1023–1032. [Google Scholar]
  121. Caito, S.; Rajendrasozhan, S.; Cook, S.; Chung, S.; Yao, H.; Friedman, A.E.; Brookes, P.S.; Rahman, I. SIRT1 is a redox sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J 2010, 24, 3145–3159. [Google Scholar]
  122. Srivastava, S.K.; Ramana, K.V.; Bhatnagar, A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev 2005, 26, 380–392. [Google Scholar]
  123. Srivastava, S.K.; Yadav, U.C.; Reddy, A.B.; Saxena, A.; Tammali, R.; Shoeb, M.; Ansari, N.H.; Bhatnagar, A.; Petrash, M.J.; Srivastava, S.; et al. Aldose reductase inhibition suppresses oxidative stress induced inflammatory disorders. Chem. Biol. Interact 2011, 191, 330–338. [Google Scholar]
  124. Ruef, J.; Liu, S.Q.; Bode, C.; Tocchi, M.; Srivastava, S.; Runge, M.S.; Bhatnagar, A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler. Thromb. Vasc. Biol 2000, 20, 1745–1752. [Google Scholar]
  125. Iwata, T.; Sato, S.; Jimenez, J.; McGowan, M.; Moroni, M.; Dey, A.; Ibaraki, N.; Reddy, V.N.; Carper, D. Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J. Biol. Chem 1999, 274, 7993–8001. [Google Scholar]
  126. Ramana, K.V.; Bhatnagar, A.; Srivastava, S.K. Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J 2004, 18, 1209–1218. [Google Scholar]
  127. Cappiello, M.; Voltarelli, M.; Cecconi, I.; Vilardo, P.G.; Dal Monte, M.; Marini, I.; Del Corso, A.; Wilson, D.K.; Quiocho, F.A.; Petrash, J.M.; et al. Specifically targeted modification of human aldose reductase by physiological disulfides. J. Biol. Chem 1996, 271, 33539–33544. [Google Scholar]
  128. Bohren, K.M.; Gabbay, K.H. Cys298 is responsible for reversible thiol-induced variation in aldose reductase activity. Adv. Exp. Med. Biol 1993, 328, 267–277. [Google Scholar]
  129. Liu, S.Q.; Bhatnagar, A.; Ansari, N.H.; Srivastava, S.K. Identification of the reactive cysteine residue in human placenta aldose reductase. Biochim. Biophys. Acta 1993, 1164, 268–272. [Google Scholar]
  130. Cappiello, M.; Amodeo, P.; Mendez, B.L.; Scaloni, A.; Vilardo, P.G.; Cecconi, I.; Dal Monte, M.; Banditelli, S.; Talamo, F.; Micheli, V.; et al. Modulation of aldose reductase activity through S-thiolation by physiological thiols. Chem. Biol. Interact 2001, 130–132, 597–608. [Google Scholar]
  131. Ramana, K.V.; Tammali, R.; Reddy, A.B.; Bhatnagar, A.; Srivastava, S.K. Aldose reductase-regulated tumor necrosis factor-alpha production is essential for high glucoseinduced vascular smooth muscle cell growth. Endocrinology 2007, 148, 4371–4384. [Google Scholar]
  132. Kaiserova, K.; Srivastava, S.; Hoetker, J.D.; Awe, S.O.; Tang, X.L.; Cai, J.; Bhatnagar, A. Redox activation of aldose reductase in the ischemic heart. J. Biol. Chem 2006, 281, 15110–15120. [Google Scholar]
  133. Kaiserova, K.; Tang, X.L.; Srivastava, S.; Bhatnagar, A. Role of nitric oxide in regulating aldose reductase activation in the ischemic heart. J. Biol. Chem 2008, 283, 9101–9112. [Google Scholar]
  134. Garel, M.C.; Domenget, C.; Caburi-Martin, J.; Prehu, C.; Galacteros, F.; Beuzard, Y. Covalent binding of glutathione to hemoglobin. I. Inhibition of hemoglobin S polymerization. J. Biol. Chem 1986, 261, 14704–14709. [Google Scholar]
  135. Craescu, C.T.; Poyart, C.; Schaeffer, C.; Garel, M.C.; Kister, J.; Beuzard, Y. Covalent binding of glutathione to hemoglobin. II. Functional consequences and structural changes reflected in NMR spectra. J. Biol. Chem 1986, 261, 14710–14716. [Google Scholar]
  136. Mawatari, S.; Murakami, K. Different types of glutathionylation of hemoglobin can exist in intact erythrocytes. Arch. Biochem. Biophys 2004, 421, 108–114. [Google Scholar]
  137. Regazzoni, L.; Panusa, A.; Yeum, K.J.; Carini, M; Aldini, G. Hemoglobin glutathionylation can occur through cysteine sulfenic acid intermediate: Electrospray ionization LTQ-Orbitrap hybrid mass spectrometry studies. J. Chromatogr. B 2009, 877, 3456–3461. [Google Scholar]
  138. Metere, A.; Iorio, E.; Scorza, G.; Camerini, S.; Casella, M.; Crescenzi, M.; Minetti, M.; Pietraforte, D. Carbon monoxide signaling in human red blood cells: evidence for pentose phosphate pathway activation and protein deglutathionylation. Antioxid. Redox Signal 2013. in press. [Google Scholar]
  139. Head, C.A.; Brugnara, C.; Martinez-Ruiz, R.; Kacmarek, R.M.; Bridges, K.R.; Kuter, D.; Bloch, K.D.; Zapol, W.M. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J. Clin. Invest. 1997, 100, 1193–1198. [Google Scholar]
  140. Jia, L.; Bonaventura, C.; Bonaventura, J.; Stamler, J.S. S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996, 380, 221–226. [Google Scholar]
  141. Singel, D.J.; Stamler, J.S. Chemical physiology of blood flow regulation by red blood cells: The role of nitric oxide and S-nitrosohemoglobin. Annu. Rev. Physiol 2005, 67, 99–145. [Google Scholar]
  142. Niwa, T. Protein glutathionylation and oxidative stress. J. Chromatogr. B 2007, 855, 59–65. [Google Scholar]
  143. Sethuraman, M.; Clavreul, N.; Huang, H.; McComb, M.E.; Costello, C.E.; Cohen, R.A. Quantification of oxidative posttranslational modifications of cysteine thiols of p21ras associated with redox modulation of activity using isotopecoded affinity tags and mass spectrometry. Free Radic. Biol. Med 2007, 42, 823–829. [Google Scholar]
  144. Zhao, C.; Sethuraman, M.; Clavreul, N.; Kaur, P.; Cohen, R.A.; O’Connor, P.B. Detailed map of oxidative post-translational modifications of human p21ras using Fourier transform mass spectrometry. Anal. Chem 2006, 78, 5134–5142. [Google Scholar]
  145. Kuster, G.M.; Pimentel, D.R.; Adachi, T.; Ido, Y.; Brenner, D.A.; Cohen, R.A.; Liao, R.; Siwik, D.A.; Colucci, W.S. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 2005, 111, 1192–1198. [Google Scholar]
  146. Takayama, N.; Kai, H.; Kudo, H.; Yasuoka, S.; Mori, T.; Anegawa, T.; Koga, M.; Kajimoto, H.; Hirooka, Y.; Imaizumi, T. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways. Hypertens. Res 2011, 34, 341–347. [Google Scholar]
  147. Shelton, M.D.; Mieyal, J.J. Regulation by reversible Sglutathionylation: Molecular targets implicated in inflammatory diseases. Mol. Cells 2008, 25, 332–346. [Google Scholar]
  148. Pineda-Molina, E.; Klatt, P.; Vazquez, J.; Marina, A.; Garcia de Lacoba, M.; Perez-Sala, D.; Lamas, S. Glutathionylation of the p50 subunit of NF-kappaB: A mechanism for redoxinduced inhibition of DNA binding. Biochemistry 2001, 40, 14134–14142. [Google Scholar]
  149. Qanungo, S.; Starke, D.W.; Pai, H.V.; Mieyal, J.J.; Nieminen, A.L. Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NFkappaB. J. Biol. Chem 2007, 282, 18427–18436. [Google Scholar]
  150. Baeuerle, P. AIkB-NF-kB structures: At the interface of inflammation control. Cell 1998, 95, 729–731. [Google Scholar]
  151. Kabe, Y.; Ando, K.; Hirao, S.; Yoshida, M.; Handa, H. Redox regulation of NFkappaB activation: Distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal 2005, 7, 395–403. [Google Scholar]
  152. Braun, T.; Carvalho, G.; Fabre, C.; Grosjean, J.; Fenaux, P.; Kroemer, G. Targeting NF-kappaB in hematologic malignancies. Cell Death. Differ 2006, 13, 748–758. [Google Scholar]
  153. Oakley, F.D.; Smith, R.L.; Engelhardt, J.F. Lipid rafts and caveolin-1 coordinate interleukin-1beta (IL-1beta)-dependent activation of NFkappaB by controlling endocytosis of Nox2 and IL-1beta receptor 1 from the plasma membrane. J. Biol. Chem 2009, 284, 33255–33564. [Google Scholar]
  154. Oakley, F.D.; Abbott, D.; Li, Q.; Engelhardt, J.F. Signaling components of redox active endosomes: The redoxosomes. Antioxid. Redox Signal 2009, 11, 1313–1333. [Google Scholar]
  155. Li, Q.; Spencer, N.Y.; Oakley, F.D.; Buettner, G.R.; Engelhardt, J.F. Endosomal Nox2 facilitates redox dependent induction of NF-kappa B by TNF-alpha. Antioxid. Redox Signal 2009, 11, 1249–1263. [Google Scholar]
  156. Prinarakis, E.; Chantzoura, E.; Thanos, D.; Spyrou, G. S-glutathionylation of IRF3 regulates IRF3-CBP interaction and activation of the IFN beta pathway. EMBO J 2008, 27, 865–875. [Google Scholar]
  157. Madhani, M.; Hall, A.R.; Cuello, F.; Charles, R.L.; Burgoyne, J.R.; Fuller, W.; Hobbs, A.J.; Shattock, M.J.; Eaton, P. Phospholemman Ser69 phosphorylation contributes to sildenafilinduced cardioprotection against reperfusion injury. Am. J. Physiol. Heart Circ. Physiol 2010, 299, H827–H836. [Google Scholar]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert